{
    "clinical_study": {
        "@rank": "82211", 
        "arm_group": [
            {
                "arm_group_label": "Ibuprofen 5% topical gel", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Topical gel vehicle", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sodium lauryl sulfate 0.1%", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sodium chloride solution 0.9% (saline)", 
                "arm_group_type": "Sham Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to determine the potential of Ibuprofen 5% Topical Gel and its\n      vehicle gel to cause sensitization after repeated topical application to healthy skin of\n      human subjects under controlled conditions."
        }, 
        "brief_title": "RIPT of Ibuprofen Topical Gel", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy male or female subjects 18 years of age or older, female subjects of childbearing\n        potential and males are using an acceptable form of birth control, subjects are free of\n        any systemic or dermatologic disorder\n\n        Exclusion Criteria:\n\n        Have any visible skin disease at the application site, not willing to stop use of systemic\n        or topical analgesics, corticosteroids, or antihistamines, not willing to stop use of\n        sunscreens, creams, or similar products on the back during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "234", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787448", 
            "org_study_id": "B3491007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ibuprofen 5% topical gel", 
                "description": "0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application", 
                "intervention_name": "Topical gel vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Topical gel vehicle", 
                "description": "0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application", 
                "intervention_name": "Topical gel vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sodium lauryl sulfate 0.1%", 
                "description": "0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application", 
                "intervention_name": "Sodium lauryl sulfate 0.1%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sodium chloride solution 0.9% (saline)", 
                "description": "0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications)  followed by 10-14 day rest period and one subsequent re-application", 
                "intervention_name": "Sodium chloride solution 0.9% (saline)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "repeat insult patch test", 
        "lastchanged_date": "February 27, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3491007&StudyName=RIPT%20of%20ibuprofen%20topical%20gel"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Carlstadt", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07652"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Repeat-insult Patch Test (Ript) of Ibuprofen 5% Topical Gel in Human Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Dermal sensitization potential", 
            "safety_issue": "Yes", 
            "time_frame": "24-72 hours after last patch removal"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cumulative Irritancy", 
                "safety_issue": "Yes", 
                "time_frame": "48-72 hours after each patch application"
            }, 
            {
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "During study through 28 days after last product application"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}